Arvinas
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
ARVN Key Statistics
Stock Snapshot
As of today, Arvinas(ARVN) shares are valued at $11.21. The company's market cap stands at 720.6M, with a P/E ratio of -13.93.
On 2025-11-11, Arvinas(ARVN) stock moved within a range of $11.10 to $11.51. With shares now at $11.21, the stock is trading +1.0% above its intraday low and -2.6% below the session's peak.
Trading volume for Arvinas(ARVN) stock has reached 2.13M, versus its average volume of 2.31M.
The stock's 52-week range extends from a low of $5.90 to a high of $28.70.
The stock's 52-week range extends from a low of $5.90 to a high of $28.70.
ARVN News
Stephens analyst Sudan Loganathan raised the firm’s price target on Arvinas (ARVN) to $15 from $14 and keeps an Overweight rating on the shares. Q3 results were...
Arvinas (ARVN) continues to operate at a loss, with net losses increasing at an average rate of 7.7% per year over the past five years and no signs of profit gr...
Earnings Call Insights Arvinas outlines plan for $100M share buyback and targets sub-$75M quarterly run rate amid pipeline expansion Nov. 05, 2025 3:02 PM ET Ar...
Analyst ratings
47%
of 19 ratingsMore ARVN News
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $1.18 pe...
Based on its current operating plan, Arvinas (ARVN) believes its cash, cash equivalents, and marketable securities as of September 30, 2025, is sufficient to fu...